ETFs to Profit from the Weight Loss Drug Boom

Zacks06-04

Two dominant investing themes over the past year have been AI and weight-loss drugs. While there's a lot of excitement around AI, particularly with NVIDIA NVDA, shares of two companies that dominate ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2441255948?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-06-04 23:45","share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","id":"2441255948","market":"us","top_or_hot":-1,"title":"ETFs to Profit from the Weight Loss Drug Boom","media":"Zacks","content":"<div>\n<p>Two dominant investing themes over the past year have been AI and weight-loss drugs. While there's a lot of excitement around AI, particularly with NVIDIA NVDA, shares of two companies that dominate ...</p>\n\n<a href=\"https://finance.yahoo.com/news/etfs-profit-weight-loss-drug-154500848.html\">Source Link</a>\n\n</div>\n","source":"yahoofinance","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>ETFs to Profit from the Weight Loss Drug Boom</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nETFs to Profit from the Weight Loss Drug Boom\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-06-04 23:45 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/etfs-profit-weight-loss-drug-154500848.html><strong>Zacks</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Two dominant investing themes over the past year have been AI and weight-loss drugs. While there's a lot of excitement around AI, particularly with NVIDIA NVDA, shares of two companies that dominate ...</p>\n\n<a href=\"https://finance.yahoo.com/news/etfs-profit-weight-loss-drug-154500848.html\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IE0004445015.USD","symbol_name":"JANUS HENDERSON BALANCED \"A2\" (USD) ACC","start_time":0,"source_url":"https://finance.yahoo.com/news/etfs-profit-weight-loss-drug-154500848.html","article_id":"2441255948","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2441255948","pubTimestamp":1717515900,"sourceInfo":{"source_id":"yahoofinance","name":"雅虎金融"},"weMediaInfo":null,"summary":"Two dominant investing themes over the past year have been AI and weight-loss drugs. While there's a lot of excitement around AI, particularly with NVIDIA NVDA, shares of two companies that dominate the weight-loss drug market have also surged over the past year due to soaring demand for their products.Shares of Eli Lilly LLY are up over 89% over the past year, and its market capitalization surpassed Tesla's TSLA earlier this year. Shares of Novo Nordisk  are up over 73%, making it the biggest European firm by market value.More than 1 billion individuals worldwide are living with obesity, a figure expected to impact over half the population by 2035. Obesity is linked to numerous health risks, including diabetes, heart disease, stroke, and cancer.GLP-1 medications mimic the effects of the naturally occurring hormone glucagon-like peptide-1, which is produced in the intestine after eating. These drugs were initially used to treat diabetes but were later found to control blood sugar level","collect":0,"end_time":0,"defaultTopTitle":"yahoo.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"IE0004445015.USD":"JANUS HENDERSON BALANCED \"A2\" (USD) ACC","LU2264538146.SGD":"Fullerton Lux Funds - Global Absolute Alpha A Acc SGD","OZEM":"Roundhill GLP-1 & Weight Loss ETF","LLY":"礼来","LU0466842654.USD":"HSBC ISLAMIC GLOBAL EQUITY INDEX \"A\" (USD) ACC","LU0882574055.USD":"富达全球健康医疗A ACC","LU0689472784.USD":"安联收益及增长基金Cl AM AT Acc","IE00B3M56506.USD":"NEUBERGER BERMAN EMERGING MARKETS EQUITY \"A\" (USD) ACC","LU1720051017.SGD":"Allianz Global Artificial Intelligence AT Acc H2-SGD","LU0289961442.SGD":"SUSTAINABLE GLOBAL THEMATIC PORTFOLIO \"AX\" (SGD) ACC","LU1861558580.USD":"日兴方舟颠覆性创新基金B","NVDA":"英伟达","LU1064131342.USD":"Fullerton Lux Funds - Global Absolute Alpha A Acc USD","LU0708995401.HKD":"FRANKLIN U.S. OPPORTUNITIES \"A\" (HKD) ACC","IE00BKVL7J92.USD":"Legg Mason ClearBridge - US Equity Sustainability Leaders A Acc USD","BK4585":"ETF&股票定投概念","IE00BJJMRZ35.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (SGDHDG) ACC","THNR":"AMPLIFY WEIGHT LOSS DRUG & TREATMENT ETF","LU0127658192.USD":"EASTSPRING INVESTMENTS GLOBAL TECHNOLOGY \"A\" (USD) ACC","LU1551013425.SGD":"Allianz Income and Growth Cl AMg2 DIS H2-SGD","LU0882574139.USD":"富达环球消费行业基金A ACC","LU0256863811.USD":"ALLIANZ US EQUITY \"A\" INC","FDN":"First Trust Dow Jones Internet I","LU2602419157.SGD":"HSBC ISLAMIC GLOBAL EQUITY INDEX \"AC\" (SGD) ACC","IE0009356076.USD":"JANUS HENDERSON GLOBAL TECHNOLOGY AND INNOVATION \"A2\" (USD) ACC","BK4587":"ChatGPT概念","LU1720051108.HKD":"ALLIANZ GLOBAL ARTIFICIAL INTELLIGENCE \"AT\" (HKD) ACC","LU0114720955.EUR":"SUSTAINABLE GLOBAL HEALTH CARE \"A\" INC","LU0943347566.SGD":"安联收益及增长平衡基金AM H2-SGD","IE0034235295.USD":"PINEBRIDGE GLOBAL DYNAMIC ASSET ALLOCATION \"A\" (USD) ACC","LU0170899867.USD":"EASTSPRING INVESTMENTS WORLD VALUE EQUITY  \"A\" (USD) ACC","LU0456855351.SGD":"JPMorgan Funds - Global Equity A (acc) SGD","IE00BJJMRX11.SGD":"Janus Henderson Balanced A Acc SGD","BK4579":"人工智能","LU0079474960.USD":"联博美国增长基金A","IE00BDCRKT87.USD":"PINEBRIDGE GLOBAL DYNAMIC ASSET ALLOCATION \"ADC\" (USD) INC","LU1623119135.USD":"Natixis Mirova Global Sustainable Equity R-NPF/A USD","LU0719512351.SGD":"JPMorgan Funds - US Technology A (acc) SGD","IE00B1XK9C88.USD":"PINEBRIDGE US LARGE CAP RESEARCH ENHANCED \"A\" (USD) ACC","HRTS":"Tema Cardiovascular and Metabolics ETF","LU0061474960.USD":"天利环球焦点基金AU Acc","IE00BJJMRY28.SGD":"Janus Henderson Balanced A Inc SGD","LU2265009873.SGD":"Eastspring Investments - Global Growth Equity AS SGD-H","LU1712237335.SGD":"Natixis Mirova Global Sustainable Equity H-R-NPF/A SGD","LU2249611893.SGD":"BNP PARIBAS ENERGY TRANSITION \"CRH\" (SGD) ACC","LU1914381329.SGD":"Allianz Best Styles Global Equity Cl ET Acc H2-SGD","LU0820561909.HKD":"ALLIANZ INCOME AND GROWTH \"AM\" (HKD) INC","NVO":"诺和诺德","LU1804176565.USD":"EASTSPRING INV GLOBAL GROWTH EQUITY \"A\" (USD) ACC","LU0058720904.USD":"联博国际健康护理基金A"},"translate_title":"ETF将从减肥药热潮中获利","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"THNR":1,"OZEM":1,"HRTS":1,"NVO":1,"NVDA":1,"FDN":0.9,"LLY":0.9},"content_text":"Two dominant investing themes over the past year have been AI and weight-loss drugs. While there's a lot of excitement around AI, particularly with NVIDIA NVDA, shares of two companies that dominate the weight-loss drug market have also surged over the past year due to soaring demand for their products.\nShares of Eli Lilly LLY are up over 89% over the past year, and its market capitalization surpassed Tesla's TSLA earlier this year. Shares of Novo Nordisk (NVO) are up over 73%, making it the biggest European firm by market value.\nMore than 1 billion individuals worldwide are living with obesity, a figure expected to impact over half the population by 2035. Obesity is linked to numerous health risks, including diabetes, heart disease, stroke, and cancer.\nGLP-1 medications mimic the effects of the naturally occurring hormone glucagon-like peptide-1, which is produced in the intestine after eating. These drugs were initially used to treat diabetes but were later found to control blood sugar levels, reduce appetite, and promote weight loss.\nRecent studies suggest that GLP-1 drugs may also slow the progression of Parkinson’s symptoms and reduce the severity of sleep apnea.\nAccording to Goldman Sachs, the market for these drugs could surge to $130 billion by 2030, with Eli Lilly and Novo Nordisk retaining about 80% of the market share.\nThere are 232 anti-obesity medications at various stages of development, according to the Financial Times. The next generation weight-loss drugs aim to reduce costs as well as common side effects like nausea and muscle loss.\nTo learn about the Tema Obesity & Cardiometabolic ETF HRTS, Roundhill GLP-1 & Weight Loss ETF OZEM and Amplify Weight Loss Drug & Treatment ETF THNR , please watch the short video above.\nWant the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report\nEli Lilly and Company (LLY) : Free Stock Analysis Report\nNVIDIA Corporation (NVDA) : Free Stock Analysis Report\nTesla, Inc. (TSLA) : Free Stock Analysis Report\nTema Obesity & Cardiometabolic ETF (HRTS): ETF Research Reports\nAmplify Weight Loss Drug & Treatment ETF (THNR): ETF Research Reports\nRoundhill GLP-1 & Weight Loss ETF (OZEM): ETF Research Reports\nTo read this article on Zacks.com click here.\nZacks Investment Research","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.2","shortVersion":"4.29.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2441255948"}